Patient characteristics at lymphoma presentation of entire cohort and comparison with study group who survived more than 3 months after chemotherapy
| . | All . | Survivors, more than 3 mo after chemotherapy . | P . |
|---|---|---|---|
| No. of subjects | 105 | 68 | — |
| Male, no./total (%) | 92/105 (88) | 61/68 (90) | χ2P =.38 |
| Median age, y (range) | 43 (22-77) | 41 (22-68) | MW U test P =.33 |
| Prior AIDS-defining illness, no./total (%) | 13/105 (12) | 9/68 (13) | χ2P =.71 |
| Median CD4, per mm3 (range) | 162 (2-814) | 178 (8-636) | MW U test P =.042 |
| On HAART at NHL diagnosis, no./total (%) | 62/105 (59) | 40/68 (59) | χ2P =.95 |
| Undetectable plasma HIV viral load at diagnosis, no./total (%) | 28/105 (27) | 21/68 (31) | χ2P =.19 |
| Stage III/IV, no./total (%) | 87/105 (83) | 53/68 (78) | χ2P =.07 |
| More than 1 extranodal site, no./total (%) | 52/105 (49) | 29/68 (43) | χ2P =.056 |
| EGOC score higher than 1, no./total (%) | 48/105 (46) | 22/68 (32) | χ2P =.002 |
| LDH level raised, no./total (%) | 72/105 (69) | 41/68 (60) | χ2P =.013 |
| IPI, no. (%) | — | — | χ2P =.002 |
| Low | 22 (21) | 19 (28) | — |
| Low intermediate | 26 (25) | 20 (29) | — |
| High intermediate | 30 (29) | 19 (28) | — |
| High | 27 (26) | 10 (15) | — |
| . | All . | Survivors, more than 3 mo after chemotherapy . | P . |
|---|---|---|---|
| No. of subjects | 105 | 68 | — |
| Male, no./total (%) | 92/105 (88) | 61/68 (90) | χ2P =.38 |
| Median age, y (range) | 43 (22-77) | 41 (22-68) | MW U test P =.33 |
| Prior AIDS-defining illness, no./total (%) | 13/105 (12) | 9/68 (13) | χ2P =.71 |
| Median CD4, per mm3 (range) | 162 (2-814) | 178 (8-636) | MW U test P =.042 |
| On HAART at NHL diagnosis, no./total (%) | 62/105 (59) | 40/68 (59) | χ2P =.95 |
| Undetectable plasma HIV viral load at diagnosis, no./total (%) | 28/105 (27) | 21/68 (31) | χ2P =.19 |
| Stage III/IV, no./total (%) | 87/105 (83) | 53/68 (78) | χ2P =.07 |
| More than 1 extranodal site, no./total (%) | 52/105 (49) | 29/68 (43) | χ2P =.056 |
| EGOC score higher than 1, no./total (%) | 48/105 (46) | 22/68 (32) | χ2P =.002 |
| LDH level raised, no./total (%) | 72/105 (69) | 41/68 (60) | χ2P =.013 |
| IPI, no. (%) | — | — | χ2P =.002 |
| Low | 22 (21) | 19 (28) | — |
| Low intermediate | 26 (25) | 20 (29) | — |
| High intermediate | 30 (29) | 19 (28) | — |
| High | 27 (26) | 10 (15) | — |
MW U indicates Mann-Whitney U test; IPI, international prognostic index; and —, not applicable.